MARK1

From Wikipedia, the free encyclopedia


MAP/microtubule affinity-regulating kinase 1
PDB rendering based on 2hak.
Available structures: 2hak
Identifiers
Symbol(s) MARK1; KIAA1477; MARK; MGC126512; MGC126513
External IDs OMIM: 606511 MGI2664902 HomoloGene49552
RNA expression pattern

More reference expression data

Orthologs
Human Mouse
Entrez 4139 226778
Ensembl ENSG00000116141 ENSMUSG00000026620
Uniprot Q9P0L2 Q14DQ3
Refseq NM_018650 (mRNA)
NP_061120 (protein)
NM_145515 (mRNA)
NP_663490 (protein)
Location Chr 1: 218.77 - 218.9 Mb Chr 1: 186.6 - 186.65 Mb
Pubmed search [1] [2]

MAP/microtubule affinity-regulating kinase 1, also known as MARK1, is a human gene.[1]


[edit] References

[edit] Further reading

  • Drewes G, Trinczek B, Illenberger S, et al. (1995). "Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262.". J. Biol. Chem. 270 (13): 7679–88. PMID 7706316. 
  • Yang SD, Yu JS, Shiah SG, Huang JJ (1994). "Protein kinase FA/glycogen synthase kinase-3 alpha after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain.". J. Neurochem. 63 (4): 1416–25. PMID 7931292. 
  • Illenberger S, Drewes G, Trinczek B, et al. (1996). "Phosphorylation of microtubule-associated proteins MAP2 and MAP4 by the protein kinase p110mark. Phosphorylation sites and regulation of microtubule dynamics.". J. Biol. Chem. 271 (18): 10834–43. PMID 8631898. 
  • Paudel HK (1997). "The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase.". J. Biol. Chem. 272 (3): 1777–85. PMID 8999860. 
  • Drewes G, Ebneth A, Preuss U, et al. (1997). "MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption.". Cell 89 (2): 297–308. PMID 9108484. 
  • Sengupta A, Kabat J, Novak M, et al. (1998). "Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules.". Arch. Biochem. Biophys. 357 (2): 299–309. doi:10.1006/abbi.1998.0813. PMID 9735171. 
  • Wang JZ, Wu Q, Smith A, et al. (1998). "Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase.". FEBS Lett. 436 (1): 28–34. PMID 9771888. 
  • Hanger DP, Betts JC, Loviny TL, et al. (1998). "New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.". J. Neurochem. 71 (6): 2465–76. PMID 9832145. 
  • Schneider A, Biernat J, von Bergen M, et al. (1999). "Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.". Biochemistry 38 (12): 3549–58. doi:10.1021/bi981874p. PMID 10090741. 
  • Reynolds CH, Betts JC, Blackstock WP, et al. (2000). "Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta.". J. Neurochem. 74 (4): 1587–95. PMID 10737616. 
  • Nagase T, Kikuno R, Ishikawa K, et al. (2000). "Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.". DNA Res. 7 (2): 143–50. PMID 10819331. 
  • Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2002). "Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.". FEBS Lett. 530 (1-3): 209–14. PMID 12387894. 
  • Liu F, Zaidi T, Iqbal K, et al. (2003). "Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5.". Neuroscience 115 (3): 829–37. PMID 12435421. 
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932. 
  • Timm T, Li XY, Biernat J, et al. (2003). "MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1.". EMBO J. 22 (19): 5090–101. doi:10.1093/emboj/cdg447. PMID 14517247. 
  • Trinczek B, Brajenovic M, Ebneth A, Drewes G (2004). "MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes.". J. Biol. Chem. 279 (7): 5915–23. doi:10.1074/jbc.M304528200. PMID 14594945. 
  • Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039. 
  • Lizcano JM, Göransson O, Toth R, et al. (2005). "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.". EMBO J. 23 (4): 833–43. doi:10.1038/sj.emboj.7600110. PMID 14976552. 
  • Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMID 15489334. 
  • Benzinger A, Muster N, Koch HB, et al. (2005). "Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer.". Mol. Cell Proteomics 4 (6): 785–95. doi:10.1074/mcp.M500021-MCP200. PMID 15778465.